IL10 released by a new inflammation-regulated lentiviral system efficiently attenuates zymosan-induced arthritis

Molecular Therapy

Volumn 21, Issue 1, 2013, Pages 119-130

  Garaulet, Guillermo ^a   Alfranca, Arántzazu ^b   Torrente, María ^a,b   Escolano, Amelia ^b   López Fontal, Raquel ^b   Hortelano, Sonsoles ^b   Redondo, Juan M ^b   Rodríguez, Antonio ^a  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^b CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; GREEN FLUORESCENT PROTEIN; INTERLEUKIN 10; LENTIVIRUS VECTOR; LUCIFERASE; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTHRITIS; ARTICLE; CHRONIC INFLAMMATION; CONTROLLED STUDY; CYTOKINE RELEASE; DOWN REGULATION; FEMALE; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; TRANSGENE; UPREGULATION; VIRAL GENE DELIVERY SYSTEM;

ANIMALIA;

EID: 84871923730     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2012.131     Document Type: Article

References (50)

1. Leung, PS, Dhirapong, A, Wu, PY and Tao, MH (2010). Gene therapy in autoimmunediseases: challenges and opportunities. Autoimmun Rev 9: 170-174.
2. Moore, KW, O'Garra, A, de Waal Malefyt, R, Vieira, P and Mosmann, TR (1993).Interleukin-10. Annu Rev Immunol 11: 165-190. (Pubitemid 23115005)
3. Oberholzer, A, Oberholzer, C and Moldawer, LL (2002). Interleukin-10: A complexrole in the pathogenesis of sepsis syndromes and its potential as an anti-inflammatorydrug. Crit Care Med 30(1 Supp): S58-S63. (Pubitemid 34131163)
4. Spera, PA, Ellison, JA, Feuerstein, GZ and Barone, FC (1998). IL-10 reduces rat braininjury following focal stroke. Neurosci Lett 251: 189-192. (Pubitemid 28381079)
5. Rott, O, Fleischer, B and Cash, E (1994). Interleukin-10 prevents experimental allergicencephalomyelitis in rats. Eur J Immunol 24: 1434-1440. (Pubitemid 24169530)
6. Steidler, L, Hans, W, Schotte, L, Neirynck, S, Obermeier, F, Falk, W et al. (2000).Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science 289:1352-1355. (Pubitemid 30656052)
7. van de Loo FA and van den Berg WB (2002). Gene therapy for rheumatoid arthritis.Lessons from animal models, including studies on interleukin-4, interleukin-10, andinterleukin-1 receptor antagonist as potential disease modulators. Rheum Dis ClinNorth Am 28: 127-149. (Pubitemid 34111681)
8. van de Loo FA (2004). Inflammation-responsive promoters for fine-tuned genetherapy in rheumatoid arthritis. Curr Opin Mol Ther 6: 537-545.
9. Varley, AW, Geiszler, SM, Gaynor, RB and Munford, RS (1997). A two-componentexpression system that responds to inflammatory stimuli in vivo. Nat Biotechnol 15:1002-1006. (Pubitemid 27425942)
10. van de Loo FA, de Hooge AS, Smeets RL, Bakker AC, Bennink MB, Arntz OJ et al.(2004). An inflammation-inducible adenoviral expression system for local treatment ofthe arthritic joint. Gene Ther 11: 581-590. (Pubitemid 38455976)
11. Khoury, M, Adriaansen, J, Vervoordeldonk, MJ, Gould, D, Chernajovsky, Y, Bigey,P et al. (2007). Inflammation-inducible anti-TNF gene expression mediated byintra-articular injection of serotype 5 adeno-associated virus reduces arthritis. JGene Med 9: 596-604. (Pubitemid 47073992)
12. Mingozzi, F and High, KA (2007). Immune responses to AAV in clinical trials. CurrGene Ther 7: 316-324. (Pubitemid 47595774)
13. Zaiss, AK, Cotter, MJ, White, LR, Clark, SA, Wong, NC, Holers, VM et al. (2008).Complement is an essential component of the immune response to adeno-associatedvirus vectors. J Virol 82: 2727-2740. (Pubitemid 351329164)
14. Peden, CS, Manfredsson, FP, Reimsnider, SK, Poirier, AE, Burger, C, Muzyczka, N et al.(2009). Striatal readministration of rAAV vectors reveals an immune response againstAAV2 capsids that can be circumvented. Mol Ther 17: 524-537.
15. Buchschacher, GL Jr and Wong-Staal, F (2000). Development of lentiviral vectors forgene therapy for human diseases. Blood 95: 2499-2504. (Pubitemid 30210526)
16. Roth, S, Pulcini, C, Vandenbos, F, Bernard, E, Dellamonica, P, Kaphan, R et al. (2002).[Pulmonary localization of hairy cell leukemia]. Rev Med Interne 23: 870-872. (Pubitemid 35221829)
17. Mayordomo, L, Marenco, JL, Gomez-Mateos, J and Rejon, E (2002). Pulmonarymiliary tuberculosis in a patient with anti-TNF-alpha treatment. Scand J Rheumatol31: 44-45. (Pubitemid 34169450)
18. Nez Martez, O, Ripoll Noiseux, C, Carneros Mart, JA, Gonzez Lara, V andGregorio Mara?n, HG (2001). Reactivation tuberculosis in a patient with anti-TNFalphatreatment. Am J Gastroenterol 96: 1665-1666.
19. Sicotte, NL and Voskuhl, RR (2001). Onset of multiple sclerosis associated with anti-TNF therapy. Neurology 57: 1885-1888. (Pubitemid 33096700)
20. Springer, TA (1994). Traffic signals for lymphocyte recirculation and leukocyteemigration: the multistep paradigm. Cell 76: 301-314. (Pubitemid 24046692)
21. Keelan, ET, Licence, ST, Peters, AM, Binns, RM and Haskard, DO (1994).Characterization of E-selectin expression in vivo with use of a radiolabeled monoclonalantibody. Am J Physiol 266(1 Pt 2): H278-H290.
22. Jaggar, RT, Chan, HY, Harris, AL and Bicknell, R (1997). Endothelial cell-specificexpression of tumor necrosis factor-alpha from the KDR or E-selectin promotersfollowing retroviral delivery. Hum Gene Ther 8: 2239-2247. (Pubitemid 28043561)
23. Walton, T, Wang, JL, Ribas, A, Barsky, SH, Economou, J and Nguyen, M (1998).Endothelium-specific expression of an E-selectin promoter recombinant adenoviralvector. Anticancer Res 18(3A): 1357-1360. (Pubitemid 28342530)
24. Xu, N, Rahman, A, Minshall, RD, Tiruppathi, C and Malik, AB (2000). beta(2)-Integrinblockade driven by E-selectin promoter prevents neutrophil sequestration and lunginjury in mice. Circ Res 87: 254-260. (Pubitemid 30626434)
25. Xu, N, Gao, XP, Minshall, RD, Rahman, A and Malik, AB (2002). Time-dependentreversal of sepsis-induced PMN uptake and lung vascular injury by expression of CD18antagonist. Am J Physiol Lung Cell Mol Physiol 282: L796-L802. (Pubitemid 34665596)
26. Maxwell, IH, Kaletta, C, Naujoks, K and Maxwell, F (2003). Targeting diphtheriatoxin A-chain transcription to activated endothelial cells using an E-selectin promoter.Angiogenesis 6: 31-38. (Pubitemid 37305337)
27. Hortelano, S, Lez-Fontal, R, Trav, PG, Villa, N, Grashoff, C, Bosc L et al. (2010).ILK mediates LPS-induced vascular adhesion receptor expression and subsequentleucocyte trans-endothelial migration. Cardiovasc Res 86: 283-292.
28. Stannard, AK, Khurana, R, Evans, IM, Sofra, V, Holmes, DI and Zachary, I (2007).Vascular endothelial growth factor synergistically enhances induction of E-selectin bytumor necrosis factor-alpha. Arterioscler Thromb Vasc Biol 27: 494-502.
29. Gir, N, Trav, PG, Rodruez, B, Lez-Fontal, R, Bosc L, Hortelano, S et al.(2008). Suppression of inflammatory responses by labdane-type diterpenoids. ToxicolAppl Pharmacol 228: 179-189.
30. Jain, NK, Ishikawa, TO, Spigelman, I and Herschman, HR (2008). COX-2expression and function in the hyperalgesic response to paw inflammation in mice.Prostaglandins Leukot Essent Fatty Acids 79: 183-190.
31. Gross, S, Gammon, ST, Moss, BL, Rauch, D, Harding, J, Heinecke, JW et al. (2009).Bioluminescence imaging of myeloperoxidase activity in vivo. Nat Med 15:455-461.
32. Esslinger, C, Chapatte, L, Finke, D, Miconnet, I, Guillaume, P, Lay, F et al. (2003). Invivo administration of a lentiviral vaccine targets DCs and induces efficient CD8(+) Tcell responses. J Clin Invest 111: 1673-1681. (Pubitemid 38057749)
33. Li, S and Huang, L (2000). Nonviral gene therapy: promises and challenges. Gene Ther7: 31-34. (Pubitemid 30077146)
34. Niidome, T and Huang, L (2002). Gene therapy progress and prospects: nonviralvectors. Gene Ther 9: 1647-1652. (Pubitemid 36104607)
35. Newman, KD, Dunn, PF, Owens, JW, Schulick, AH, Virmani, R, Sukhova, G et al.(1995). Adenovirus-mediated gene transfer into normal rabbit arteries results inprolonged vascular cell activation, inflammation, and neointimal hyperplasia. J ClinInvest 96: 2955-2965.
36. Hiltunen, MO, Turunen, MP, Turunen, AM, Rissanen, TT, Laitinen, M, Kosma, VM et al.(2000). Biodistribution of adenoviral vector to nontarget tissues after local in vivo genetransfer to arterial wall using intravascular and periadventitial gene delivery methods.FASEB J 14: 2230-2236.
37. Pajusola, K, Gruchala, M, Joch, H, Lcher, TF, YlHerttuala, S and Bler, H(2002). Cell-type-specific characteristics modulate the transduction efficiency ofadeno-associated virus type 2 and restrain infection of endothelial cells. J Virol 76:11530-11540. (Pubitemid 35231309)
38. Eslami, MH, Gangadharan, SP, Sui, X, Rhynhart, KK, Snyder, RO and Conte, MS(2000). Gene delivery to in situ veins: differential effects of adenovirus and adenoassociatedviral vectors. J Vasc Surg 31: 1149-1159. (Pubitemid 30418486)
39. Vassalli, G, Baler, H, Dudler, J, von Segesser, LK and Kappenberger, L (2003). Adenoassociatedvirus (AAV) vectors achieve prolonged transgene expression in mousemyocardium and arteries in vivo: a comparative study with adenovirus vectors. Int JCardiol 90: 229-238. (Pubitemid 37087882)
40. van Strien, ME, Mercier, D, Drukarch, B, Brev JJ, Poole, S, Binnekade, R et al. (2010).Anti-inflammatory effect by lentiviral-mediated overexpression of IL-10 or IL-1receptor antagonist in rat glial cells and macrophages. Gene Ther 17: 662-671.
41. VandenDriessche, T, Naldini, L, Collen, D and Chuah, MK (2002). Oncoretroviral andlentiviral vector-mediated gene therapy. Meth Enzymol 346: 573-589. (Pubitemid 41103160)
42. Burns, JC, Friedmann, T, Driever, W, Burrascano, M and Yee, JK (1993). Vesicularstomatitis virus G glycoprotein pseudotyped retroviral vectors: concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells. ProcNatl Acad Sci USA 90: 8033-8037. (Pubitemid 23260849)
43. Bartz, SR, Rogel, ME and Emerman, M (1996). Human immunodeficiency virustype 1 cell cycle control: Vpr is cytostatic and mediates G2 accumulation bya mechanism which differs from DNA damage checkpoint control. J Virol 70:2324-2331. (Pubitemid 26087595)
44. Oberholzer, A, Oberholzer, C, Efron, PA, Scumpia, PO, Uchida, T, Bahjat, K et al.(2005). Functional modification of dendritic cells with recombinant adenovirusencoding interleukin 10 for the treatment of sepsis. Shock 23: 507-515. (Pubitemid 40677422)
45. Kushwah, R, Oliver, JR, Duan, R, Zhang, L, Keshavjee, S and Hu, J (2012). Induction ofimmunological tolerance to adenoviral vectors by using a novel dendritic cell-basedstrategy. J Virol 86: 3422-3435.
46. Bongartz, T, Sutton, AJ, Sweeting, MJ, Buchan, I, Matteson, EL and Montori, V(2006). Anti-TNF antibody therapy in rheumatoid arthritis and the risk of seriousinfections and malignancies: systematic review and meta-analysis of rare harmfuleffects in randomized controlled trials. JAMA 295: 2275-2285. (Pubitemid 43736578)
47. Scott, DL and Kingsley, GH (2006). Tumor necrosis factor inhibitors for rheumatoidarthritis. N Engl J Med 355: 704-712.
48. Chan, JM, Villarreal, G, Jin, WW, Stepan, T, Burstein, H and Wahl, SM(2002). Intraarticular gene transfer of TNFR:Fc suppresses experimental arthritis withreduced systemic distribution of the gene product. Mol Ther 6: 727-736. (Pubitemid 36054306)
49. Scherr, M, Battmer, K, Blaer, U, Ganser, A and Grez, M (2001). Quantitativedetermination of lentiviral vector particle numbers by real-time PCR. BioTechniques 31:520, 522, 524, passim.
50. Herndez, GL, Volpert, OV, Iguez, MA, Lorenzo, E, Martez-Martez, S, Grau,R et al. (2001). Selective inhibition of vascular endothelial growth factor-mediatedangiogenesis by cyclosporin A: roles of the nuclear factor of activated T cells andcyclooxygenase 2. J Exp Med 193: 607-620. (Pubitemid 32539557)